Advertisement

Neurological Sciences

, Volume 40, Issue 1, pp 199–201 | Cite as

Six-year clinical and MRI quantitative susceptibility mapping (QSM) follow-up in neurological Wilson’s disease under zinc therapy: a case report

  • D. Zaino
  • I. Chiarotti
  • C. Battisti
  • S. Salvatore
  • A. Federico
  • A. Cerase
Letter to the Editor
  • 53 Downloads

To the Editor,

Wilson’s disease (WD) is an inherited disorder of copper metabolism, resulting in pathological accumulation of copper, principally in the liver, brain and cornea. The causative gene is ATP7B (13q14.3) that encodes a copper-transporting P-type ATPase. Liver or neuropsychiatric involvement is a hallmark of the disease [1]. Copper chelators or zinc salts are commonly given as therapy, although there is no international consensus on first-line therapy. Improvement in T2-signal alterations in follow-up brain MRI have been documented in WD patients undergoing zinc treatment (zinc sulfate) [2]. Recent studies have shown that copper deposit may result in a measurable difference in quantitative susceptibility mapping (QSM) at brain MRI of neurological and non-neurological WD patients compared to healthy controls at field strength of 7T [3], as well as in young patients with neurological WD even before T1 or T2 brain signal alteration at 1.5T [4]. Herein, we report a significant...

Notes

Acknowledgments

We wish to thank Dr. Yi Wang (Ph.D.), Dr. Pascal Spincemaille (Ph.D.), and colleagues from the Department of Radiology, Weill Cornell Medical College (New York, USA), for developing the MEDI_toolbox and for their valuable help and suggestions.

Compliance with ethical standards

Patient consent was obtained. Details have been removed from this case report to ensure anonymity.

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Bandmann O., Weiss KH, Kaler SG. (2015) Wilson’s disease and other neurological copper disorders. Lancet Neurol;14(1): 103–113. https:// doi:  https://doi.org/10.1016/S1474-4422(14)70190-5
  2. 2.
    Huang CC, Chu NS (1996) Wilson’s disease: resolution of MRI lesions following long-term oral zinc therapy. Acta Neurol Scand 93:215–218CrossRefGoogle Scholar
  3. 3.
    Fritzsch D, Reiss-Zimmermann M, Trampel R, Turner R, Hoffmann KT, Schäfer A (2014 May) Seven tesla magnetic resonance imaging in Wilson disease using quantitative susceptibility mapping for measurement of copper accumulation. Investig Radiol 49(5):299–306CrossRefGoogle Scholar
  4. 4.
    Doganay S, Gumus K, Koc G, Bayram AK, Dogan MS, Arslan D, Gumus H, Gorkem SB, Ciraci S, Serin HI, Coskun A (2018) Magnetic susceptibility changes in the basal ganglia and brain stem of patients with Wilson’s disease: evaluation with quantitative susceptibility mapping. Magn Reson Med Sci 17(1):73–79. https://doi.  https://doi.org/10.2463/mrms.mp.2016-0145
  5. 5.
    Czlonkowska A, Litwin T, Karliński M, Dziezyc K, Chabik G, Czerska M (2014) Dpenicillamine versus zinc sulphate as first-line therapy for Wilson’s disease. Eur J Neurol 4:599–606. https://doi.  https://doi.org/10.1111/ene.12348

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Medical, Surgical and Neurological SciencesUniversity of SienaSienaItaly
  2. 2.Neuroimaging and Neurointervention Unit, Department of Neurological and Sensorineural Neurosciences, Azienda Ospedaliera Universitaria SenesePoliclinico “Santa Maria alle Scotte”SienaItaly

Personalised recommendations